Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?

Last week, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), on separate days, recommended approving Pfizer’s PFE and GSK’s GSK respective respiratory syncytial virus (RSV) vaccines.

Both companies seek FDA approval for the use of their respective vaccines to prevent lower respiratory tract disease (LRTD) caused by RSV in older adults (aged 60 years and above). With the FDA granting priority review to the regulatory filings for both vaccines, a final decision on both vaccines is expected in May 2023.